Potential Negative Effects of Dextromethorphan as an Add-On Therapy to Methylphenidate in Children With ADHD

Wei-Chen Chuang, Chin-Bin Yeh, Sheng-Chiang Wang, Pei-Yin Pan, Jia-Fwu Shyu, Yia-Ping Liu, Susan Shur-Fen Gau, Ru-Band Lu, Wei-Chen Chuang, Chin-Bin Yeh, Sheng-Chiang Wang, Pei-Yin Pan, Jia-Fwu Shyu, Yia-Ping Liu, Susan Shur-Fen Gau, Ru-Band Lu

Abstract

Objectives: Methylphenidate (MPH) is highly effective in controlling the symptoms of attention-deficit/hyperactivity disorder (ADHD), but some children with ADHD either do not respond to, or do not tolerate, treatment. Dextromethorphan (DM) is a neuroprotective agent which has been used in the treatment of neuropsychiatric disorders. This clinical trial had examined the effect of DM on the use of MPH in the children with ADHD. Methods: This randomized double-blind clinical trial had evaluated 44 male outpatients, aged between 6 and 12 years, with a diagnosis of ADHD. The study subjects were randomly assigned into one of the two groups: receiving MPH alone (15-60 mg per day) or MPH plus DM (30-60 mg per day) for 8 weeks. Assessments, comprising the Chinese version of the Child Behavior Checklist (CBCL-C) scale and the Swanson, Nolan and Pelham Questionnaire (SNAP)-IV rating tests conducted by parents and the serum cytokines measured by microarray and enzyme-linked immunosorband assay (ELISA), were compared between groups at baseline and at 8 weeks after the medication was started. Results: There were a significant decrease at the mean scores of both CBCL-C and SNAP-IV scales after 8 weeks of treatment, but no significant differences between MPH and MPH+DM groups. Compared with the MPH-only group, the mean scores of some psychometric parameters reported on the CBCL-C and SNAP-IV scales regarding time effects as well as the attention problems on the CBCL-C scale regarding group effect were significantly higher in the DM+MPH group. Although there were no significant differences in the levels of various serum cytokines between groups, the subjects in the DM-MPH group had relatively fewer and lower levels of adverse effects. Significant interactions were found between the withdrawn/depression item reported on the CBCL-C scale and tumor necrosis factor α (ခTNF-α) (p = 0.027), as well as between thought problems item on the CBCL-C and TNF-α (p = 0.028) in subjects who had received DM+MPH treatment. Conclusion: Following the trial, DM+MPH was not superior to MPH alone for the treatment of children with ADHD, yet DM may potentially have negative effects on ADHD symptoms when combined with MPH. Clinical Trial Registration: Clinicaltrials.gov, trial number: NCT01787136.

Keywords: ADHD; added-on therapy; children; cytokines; dextromethorphan; methylphenidate.

Figures

Figure 1
Figure 1
Flow Diagram of Participants.

References

    1. Doernberg E, Hollander E. Neurodevelopmental Disorders (ASD and ADHD): DSM-5, ICD-10, and ICD-11. CNS Spectr (2016) 21(4):295–9. 10.1017/S1092852916000262
    1. Schans JV, Cicek R, de Vries TW, Hak E, Hoekstra PJ. Association of atopic diseases and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. Neurosci Biobehav Rev (2017) 74(Pt A):139–48. 10.1016/j.neubiorev.2017.01.011
    1. Misener VL, Schachar R, Ickowicz A, Malone M, Roberts W, Tannock R, et al. Replication test for association of the IL-1 receptor antagonist gene, IL1RN, with attention-deficit/hyperactivity disorder. Neuropsychobiology (2004) 50(3):231–4. 10.1159/000079976
    1. Lasky-Su J, Anney RJ, Neale BM, Franke B, Zhou K, Maller JB, et al. Genome-wide association scan of the time to onset of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2008) 147B(8):1355–8. 10.1002/ajmg.b.30869
    1. Lasky-Su J, Neale BM, Franke B, Anney RJ, Zhou K, Maller JB, et al. Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B Neuropsychiatr Genet (2008) 147B(8):1345–54. 10.1002/ajmg.b.30867
    1. Oades RD, Myint AM, Dauvermann MR, Schimmelmann BG, Schwarz MJ. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention. Behav Brain Funct (2010) 6:32. 10.1186/1744-9081-6-32
    1. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res (1994) 643(1–2):40–9. 10.1016/0006-8993(94)90006-X
    1. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther (2003) 304(1):1–7. 10.1124/jpet.102.035048
    1. Barcia C, Hunot S, Guillemin GJ, Pitossi F. Inflammation and Parkinson’s disease. Parkinsons Dis (2011) 2011:729054. 10.4061/2011/729054
    1. Serati M, Barkin JL, Orsenigo G, Altamura AC, Buoli M. Research Review: the role of obstetric and neonatal complications in childhood attention deficit and hyperactivity disorder - a systematic review. J Child Psychol Psychiatry (2017) 58(12):1290–300. 10.1111/jcpp.12779
    1. Chase TD, Carrey N, Brown RE, Wilkinson M. Methylphenidate differentially regulates c-fos and fosB expression in the developing rat striatum. Brain Res Dev Brain Res (2005) 157(2):181–91. 10.1016/j.devbrainres.2005.04.003
    1. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry (2018) 5(9):727–38. 10.1016/S2215-0366(18)30269-4
    1. Itzhak Y, Ali SF. Role of nitrergic system in behavioral and neurotoxic effects of amphetamine analogs. Pharmacol Ther (2006) 109(1–2):246–62. 10.1016/j.pharmthera.2005.08.004
    1. Auci DL, Fikrig S, Rodriquez J. Methylphenidate and the immune system. J Am Acad Child Adolesc Psychiatry (1997) 36(8):1015–6. 10.1097/00004583-199708000-00004
    1. Kern JK, Geier DA, King PG, Sykes LK, Mehta JA, Geier MR. Shared brain connectivity issues, symptoms, and comorbidities in autism spectrum disorder, attention deficit/hyperactivity Disorder, and Tourette Syndrome. Brain Connect (2015) 5(6):321–35. 10.1089/brain.2014.0324
    1. Storebo OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ (2015) 351:h5203. 10.1136/bmj.h5203
    1. NIDA Stimulant ADHD medications: methylphenidate and amphetamines. National Institute on Drug Abuse; (2014). p. 1–3 Available from: .
    1. De Sousa A, Kalra G. Drug therapy of attention deficit hyperactivity disorder: current trends. Mens Sana Monogr (2012) 10(1):45–69. 10.4103/0973-1229.87261
    1. Shin EJ, Bach JH, Lee SY, Kim JM, Lee J, Hong JS, et al. Neuropsychotoxic and neuroprotective potentials of dextromethorphan and its analogs. J Pharmacol Sci (2011) 116(2):137–48. 10.1254/jphs.11R02CR
    1. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience (2002) 110(1):49–58. 10.1016/S0306-4522(01)00562-0
    1. Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther (2000) 295(1):125–32.
    1. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem (2002) 81(6):1285–97. 10.1046/j.1471-4159.2002.00928.x
    1. Gayle DA, Ling Z, Tong C, Landers T, Lipton JW, Carvey PM. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res (2002) 133(1):27–35. 10.1016/S0165-3806(01)00315-7
    1. McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, Carvey PM. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol (2001) 169(2):219–30. 10.1006/exnr.2001.7688
    1. Ciesielska A, Joniec I, Przybylkowski A, Gromadzka G, Kurkowska-Jastrzebska I, Czlonkowska A, et al. Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson’s disease. Acta Neurobiol Exp (Wars) (2003) 63(2):117–26.
    1. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson’s disease. Eur J Neurosci (2003) 18(10):2731–42. 10.1111/j.1460-9568.2003.03014.x
    1. Lee DO, Ousley OY. Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol (2006) 16(6):737–46. 10.1089/cap.2006.16.737
    1. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, et al. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem (2004) 279(2):1415–21. 10.1074/jbc.M307657200
    1. Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV, et al. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage (2007) 34(3):1182–90. 10.1016/j.neuroimage.2006.10.014
    1. Guze SB. Diagnostic and Statistical Manual of Mental Disorders, 4th ed Am J Psychiatry (1995) 152(8):1228–. 10.1176/ajp.152.8.1228
    1. Liu Y, Qin L, Li G, Zhang W, An L, Liu B, et al. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther (2003) 305(1):212–8. 10.1124/jpet.102.043166
    1. Chen SL, Lee SY, Chang YH, Chen PS, Lee IH, Wang TY, et al. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. Eur Neuropsychopharmacol (2014) 24(11):1753–9. 10.1016/j.euroneuro.2014.09.001
    1. Kelly TF, Lieberman DZ. The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. J Affect Disord (2014) 167:333–5. 10.1016/j.jad.2014.05.050
    1. Lauterbach EC. Treatment resistant depression with loss of antidepressant response: rapid-acting antidepressant action of dextromethorphan, a possible treatment bridging molecule. Psychopharmacol Bull (2016) 46(2):53–8.
    1. Woodard C, Groden J, Goodwin M, Shanower C, Bianco J. The treatment of the behavioral sequelae of autism with dextromethorphan: a case report. J Autism Dev Disord (2005) 35(4):515–8. 10.1007/s10803-005-5041-z
    1. Woodard C, Groden J, Goodwin M, Bodfish J. A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. Autism (2007) 11(1):29–41. 10.1177/1362361307070989
    1. Chien YH, Lin MI, Weng WC, Du JC, Lee WT. Dextromethorphan in the treatment of early myoclonic encephalopathy evolving into migrating partial seizures in infancy. J Formos Med Assoc (2012) 111(5):290–4. 10.1016/j.jfma.2012.03.007
    1. Maxeiner HG, Marion Schneider E, Kurfiss ST, Brettschneider J, Tumani H, Bechter K. Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. Cytokine (2014) 69(1):62–7. 10.1016/j.cyto.2014.05.008
    1. Cheng J, Xiong Z, Duffney LJ, Wei J, Liu A, Liu S, et al. Methylphenidate exerts dose-dependent effects on glutamate receptors and behaviors. Biol Psychiatry (2014) 76(12):953–62. 10.1016/j.biopsych.2014.04.003
    1. Donfrancesco R, Nativio P, Borrelli E, Giua E, Andriola E, Villa MP, et al. Serum cytokines in paediatric neuropsychiatric syndromes: focus on attention deficit hyperactivity disorder. Minerva Pediatr (2016) 68(6). [Epub ahead of print].
    1. Wright MJ, Jr., Vann RE, Gamage TF, Damaj MI, Wiley JL. Comparative effects of dextromethorphan and dextrorphan on nicotine discrimination in rats. Pharmacol Biochem Behav (2006) 85(3):507–13. 10.1016/j.pbb.2006.09.020
    1. Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One (2014) 9(2):e89985. 10.1371/journal.pone.0089985
    1. Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta(R)) clinical use. Pharmacol Ther (2016) 164:170–82. 10.1016/j.pharmthera.2016.04.010
    1. Nofziger JL, Paxos C, Emshoff J, Mullen C. Evaluation of dextromethorphan with select antidepressant therapy for the treatment of depression in the acute care psychiatric setting. Mental Health Clinician (2019) 9(2):76–81. 10.9740/mhc.2019.03.076
    1. Corominas-Roso M, Ramos-Quiroga JA, Ribases M, Sanchez-Mora C, Palomar G, Valero S, et al. Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol (2013) 16(6):1267–75. 10.1017/S1461145712001629
    1. Amiri A, Torabi Parizi G, Kousha M, Saadat F, Modabbernia MJ, Najafi K, et al. Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry (2013) 47:20–4. 10.1016/j.pnpbp.2013.07.018
    1. Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci (2013) 14(1):7–23. 10.1038/nrn3379
    1. Tsai SJ. Role of neurotrophic factors in attention deficit hyperactivity disorder. Cytokine Growth Factor Rev (2017) 34:35–41. 10.1016/j.cytogfr.2016.11.003
    1. Ramos-Quiroga JA, Corominas-Roso M, Palomar G, Gomez-Barros N, Ribases M, Sanchez-Mora C, et al. Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine. Psychopharmacology (Berl) (2014) 231(7):1389–95. 10.1007/s00213-013-3343-y
    1. Cooper J. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR). Washington, DC: The American Psychiatric Association; (2001).
    1. Achenbach TM. Manual for the Child Behavior Checklist/4-18 and 1991 Profile. Burlington, VT: University of Vermont Department of Psychiatry; (1991).
    1. Morton WA, Stockton GG. Methylphenidate abuse and psychiatric side effects. Prim Care Companion J Clin Psychiatry (2000) 2(5):159–64. 10.4088/PCC.v02n0502
    1. Leung PW, Kwong SL, Tang CP, Ho TP, Hung SF, Lee CC, et al. Test-retest reliability and criterion validity of the Chinese version of CBCL, TRF, and YSR. J Child Psychol Psychiatry (2006) 47(9):970–3. 10.1111/j.1469-7610.2005.01570.x
    1. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry (2001) 40(2):168–79. 10.1097/00004583-200102000-00011
    1. Correia Filho AG, Bodanese R, Silva TL, Alvares JP, Aman M, Rohde LA. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry (2005) 44(8):748–55. 10.1097/01.chi.0000166986.30592.67
    1. Yang HJ, Soong WT, Chiang CN, Chen WJ. Competence and behavioral/emotional problems among Taiwanese adolescents as reported by parents and teachers. J Am Acad Child Adolesc Psychiatry (2000) 39(2):232–9. 10.1097/00004583-200002000-00024
    1. Ivanova MY, Dobrean A, Dopfner M, Erol N, Fombonne E, Fonseca AC, et al. Testing the 8-syndrome structure of the child behavior checklist in 30 societies. J Clin Child Adolesc Psychol (2007) 36(3):405–17. 10.1080/15374410701444363
    1. Chang LY, Wang MY, Tsai PS. Diagnostic accuracy of rating scales for attention-deficit/hyperactivity disorder: a meta-analysis. Pediatrics (2016) 137(3):e20152749. 10.1542/peds.2015-2749
    1. Wang LJ, Chen CK, Huang YS. Changes in behaviour symptoms of patients with attention deficit/hyperactivity disorder during treatment: observation from different informants. Psychiatry Investig (2013) 10(1):1–7. 10.4306/pi.2013.10.1.1
    1. Gau SS-F, Shang C-Y, Liu S-K, Lin C-H, Swanson JM, Liu Y-C, et al. Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, version IV scale—parent form. Int J Methods in Psychiatric Research (2008) 17(1):35–44. 10.1002/mpr.237
    1. Orban SA, Rapport MD, Friedman LM, Eckrich SJ, Kofler MJ. Inattentive behavior in boys with ADHD during classroom instruction: the mediating role of working memory processes. J Abnorm Child Psychol (2018) 46(4):713–27. 10.1007/s10802-017-0338-x
    1. Van den Driessche C, Bastian M, Peyre H, Stordeur C, Acquaviva E, Bahadori S, et al. Attentional lapses in attention-deficit/hyperactivity disorder: blank rather than wandering thoughts. Psychol Sci (2017) 28(10):1375–86. 10.1177/0956797617708234
    1. Pozzi L, Baviera M, Sacchetti G, Calcagno E, Balducci C, Invernizzi RW, et al. Attention deficit induced by blockade of N-methyl d-aspartate receptors in the prefrontal cortex is associated with enhanced glutamate release and cAMP response element binding protein phosphorylation: role of metabotropic glutamate receptors 2/3. Neuroscience (2011) 176:336–48. 10.1016/j.neuroscience.2010.11.060
    1. Levin ED, Bushnell PJ, Rezvani AH. Attention-modulating effects of cognitive enhancers. Pharmacol Biochem Behav (2011) 99(2):146–54. 10.1016/j.pbb.2011.02.008
    1. Mitchell RHB, Goldstein BI. Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review. J Am Acad Child Adolesc Psychiatry (2014) 53(3):274–96. 10.1016/j.jaac.2013.11.013
    1. Anand D, Colpo GD, Zeni G, Zeni CP, Teixeira AL. Attention-deficit/hyperactivity disorder and inflammation: what does current knowledge tell us? A systematic review. Front Psychiatry (2017) 8:228. 10.3389/fpsyt.2017.00228
    1. Leffa DT, Torres ILS, Rohde LA. A review on the role of inflammation in attention-deficit/hyperactivity disorder. Neuroimmunomodulation (2018) 25(5–6):328–33. 10.1159/000489635
    1. Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res (2012) 9(6):746–58. 10.2174/156720512801322564
    1. Ciccone PE, Ramabadran K, Jessen LM. Potential interactions of methylphenidate and atomoxetine with dextromethorphan. J Am Pharm Assoc (2003) (2006) 46(4):472–8. 10.1331/154434506778073600
    1. Wang CX, Shuaib A. Involvement of inflammatory cytokines in central nervous system injury. Progr Neurobiol (2002) 67(2):161–72. 10.1016/S0301-0082(02)00010-2
    1. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci (2001) 2(10):734–44. 10.1038/35094583
    1. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson’s disease. Trends Pharmacol Sci (2003) 24(8):395–401. 10.1016/S0165-6147(03)00176-7
    1. Brymer KJ, Romay-Tallon R, Allen J, Caruncho HJ, Kalynchuk LE. Exploring the potential antidepressant mechanisms of TNFα antagonists. Front Neurosci (2019) 13(98):1–9. 10.3389/fnins.2019.00098

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren